330350 — Withus Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Withus Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	57,419	64,680	80,119	102,722	106,444
Cost of Revenue
Gross Profit	33,525	38,335	48,638	65,554	68,830
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	52,533	59,803	72,210	97,266	102,600
Operating Profit	4,886	4,878	7,909	5,456	3,844
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,240	4,158	9,141	5,139	4,514
Provision for Income Taxes
Net Income After Taxes	4,264	2,479	7,959	4,785	4,967
Net Income Before Extraordinary Items
Net Income	4,264	2,479	7,959	4,785	4,967
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,264	2,479	7,959	4,785	4,967
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	347	187	603	377	466
Dividends per Share